Treatments for generalized anxiety disorder

References

• Kessler R, McGonagle K, Zhao S et al Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the national comorbidity survey. Amh. Gen. Bychiatry 51(1), 8–19 (1994).
   Google Scholar
• Wittchen H, Zhao S, Kessler R, Eaton W DSM-III-R generalized anxiety disorder in the national comorbidity survey. Arch. Gen. Psychiatry51(5), 355–364 (1994).
   Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders OSM-10. Fourth Edition. American Psychiatric Association, Washington DC, USA (1994).
   Google Scholar
• Kessler R, DuPont R, Berglund P, Wittchen H. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am. J. PFhiatry156(12), 1915-1923 (1999).
   Google Scholar
• Should children take antidepressants? Harv. Ment. Health Lett. 20(6), 5–7 (2003).
   Google Scholar
• Ballenger J. Clinical guidelines for establishing remission in patients with depression and anxiety. J. Gun. Psych. 60\(Suppl. 22), 29–34 (1999).
   Google Scholar
• Di Nardo P, O'Brien G, Barlow D, Waddell M, Blanchard E. Reliability of DSM-III anxiety disorder categories using a new structured interview. Arch. Gen. Psychiatry 40(10), 1070–1074 (1983).
   Google Scholar
• Rapee R. Generalized anxiety disorder: a review of clinical features and theoretical concepts. Clin. Psycho" Rev (11), 419–440 (1991).
   Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental DisordersThin] Edition.American Psychiatric Association, Washington DC, USA (1987).
   Google Scholar
• Rickels K, DeMartinis N, Aufdembrinke B. A double-blind, placebo-controlled trial of abecarnil and diazepam in the treatment of patients with generalized anxiety disorder. .1. Clin. Bychopharmacol. 20(1), 12–18 (2000).
   Google Scholar
• Salzman C, Miyawaki E, Le BP, Kerrihard T Neurobiologic basis of anxiety and its treatment. Harv. Rev PFhiatry1(4), 197–206 (1993).
   PubMed Web of Science ®Google Scholar
• Rickels K, Fox I, Greenblatt D, Sandler K, Schless A. Clorazepate and lorazepam: Clinical improvement and rebound anxiety. Am. fiychMtry145(3), 312–317 (1988).
   Google Scholar
• Rickels K, Schweizer E, Csanalosi I et al Long-term treatment of anxiety and risk of withdrawal: prospective comparison of course and buspirone. Awl?. Gen. Psychiatry 45,444–450 (1988).
   PubMed Web of Science ®Google Scholar
• Rickels K, Schweizer E, De Martinis N, Mandos L, Mercer C. Gepirone and diazepam in generalized anxiety disorder: a placebo-controlled trial. j Clin. Psychopharmacol. 17(4), 272–277 (1997).
   Google Scholar
• Shader R, Greenblatt D. Use of benzodiazepines in anxiety disorders. N Eng. Merl 328(19), 1398–1405 (1993).
   Google Scholar
• Bertolino A, Mastucci E, Porro V et al. Etizolam in the treatment of generalized anxiety disorder: a controlled clinical trial. .1. Int. Med. Res. 17(5), 455–460 (1989).
   Google Scholar
• Casacchia M, Bolino F, Ecari U. Etizolam in the treatment of generalized anxiety disorder: a double-blind study versus placebo. Curl: Med. Res. Opin. 12(4), 215–223 (1990).
   Google Scholar
• Ross C, Matas M. A clinical trial of buspirone and diazepam in the treatment of generalized anxiety disorder. Can. J. PTchiatry 32 (5), 351–355 (1987) .
   Google Scholar
• de Jonghe F, Swinkels J, Tuynman-Qua H, Jonkers E A comparative study of suriclone, lorazepam and placebo in anxiety disorder. Pharmacopsychiatry22(6), 266–271 (1989).
   PubMed Web of Science ®Google Scholar
• Hoehn-Saric R, McLeod D, Zimmerli W Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J. Clin. Psych. 49,293–301 (1988).
   Google Scholar
• Pourmotabbed T, Mcleod D, Hoehn-Saric R, Hipsley P, Greenblatt D. Treatment, discontinuation and psychomotor effects of diazepam in women with generalized anxiety disorder. J. Clin. Psychopharmacol. 16(3), 202–207 (1996).
   Google Scholar
• Rocca P, Fonzo V, Scotta M, Zanalda E, Ravizza L. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta PTchiatr: Scam/. 95(5), 444–450 (1997).
   PubMed Web of Science ®Google Scholar
• Lydiard R, Laraia M, Ballenger J, Howell E. Emergence of depressive symptoms in patients receiving alprazolam for panic disorder. Am. J. Psychiatry 144(5), 664–665 (1987).
   Google Scholar
• Rogers M, Warshaw M, Goisman R et al Comparing primary and secondary generalized anxiety disorder in a long-term naturalistic study of anxiety disorders. Depress. Anxiety 10(1), 1–7 (1999).
   PubMed Web of Science ®Google Scholar
• Mahe V, Balogh A. Long-term pharmacological treatment of generalized anxiety disorder. Int. Clin. Psychopharmacol. 15(2), 99–105 (2000).
   Google Scholar
• Cutler N, Sramek J, Wardle T, Kurtz N, Kashkin K, Heller A. Double-blind, placebo-controlled, parallel-group comparison study of the efficacy and safety of ipsapirone and lorazepam in outpatients with generalized anxiety disorder. Biol. fiychiatry2, 901–904 (1991).
   Google Scholar
• Ninan P. The functional anatomy, neurochemistry and pharmacology of anxiety. J. Clin. fiych. 60\(Suppl. 22), 12–17 (1999).
   Google Scholar
• Schweizer E, Rickets K, Case W Greenblatt D. Long-term therapeutic use of benzodiazepines. Effects of gradual taper. Arch. Gen. Psychiatry 47(10), 908–915 (1990).
   Google Scholar
• Laakmann G, Schule C, Lorkowski G, Baghai T, Kuhn K, Ehrentraut S. Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients. fiychophatmacology136 (4), 357–366 (1998).
   PubMed Web of Science ®Google Scholar
• Sramek J, Frackiewicz E, Cutler N. Efficacy and safety of two dosing regimens of buspirone in the treatment of outpatients with persistent anxiety. Clin. Ther 19(3), 498–506 (1997).
   Google Scholar
• Pollack M, Worthington J, Manfro G, Otto M, Zucker B. Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone. j Clin. fiychiatry58 (Suppl. 11), 19–23 (1997).
   Google Scholar
• Feighner J. Buspirone in the long-term treatment of generalized anxiety disorder. J. Clin. Psych. 48(Suppl.), 3–6 (1987).
   Google Scholar
• Pecknold J, Matas M, Howarth B et al Evaluation of buspirone as an antianxiety agent: buspirone and diazepam versus placebo. Can. J. Psychiatry 34 (8), 766–771 (1989).
   Google Scholar
• Ansseau M, Olie J, von FR, Jourdain G, Stehle B, Guillet P. Controlled comparison of the efficacy and safety of four doses of suriclone, diazepam and placebo in generalized anxiety disorder. fiychophatmacology104 (4), 439–443 (1991).
   PubMed Web of Science ®Google Scholar
• Strand M, Hetta J, Rosen A et al A double- blind, controlled trial in primary care patients with generalized anxiety: a comparison between buspirone and oxazepam. j Clin. Psych. 51 (Suppl.), 40–45 (1990).
   Google Scholar
• Enkelmann R. Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology105,428–432 (1991).
   PubMed Web of Science ®Google Scholar
• Cutler N, Sramek J, Keppel HJ et al. A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective multicenter trial. J. Clin. Psychopharmacol. 13(6), 429–437 (1993).
   Google Scholar
• Cutler N, Hesselink J, Sramek J. A Phase II multicenter dose-finding, efficacy and safety trial of ipsapirone in outpatients with generalized anxiety disorder. Frog: Neumpsychophatmacol. Biol. fiych. 18(3), 447–463 (1994).
   Google Scholar
• Boyer W, Feighner J. A placebo-controlled double-blind multicenter trial of two doses of ipsapirone versus diazepam in generalized anxiety disorder. Int. Clin. Psychopharmacol. 8(3), 173–176 (1993).
   Google Scholar
• Rickels K, Schweizer E. The clinical presentation of generalized anxiety in primary-care settings: practical concepts of classification and management. J. Clin. Psych. 58\(Suppl. 11), 4–10 (1997).
   Google Scholar
• Rickels K, De Martinis N, Garcia-Espana F, Greenblatt D, Mandos L, Rynn M. Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapy. Am. J. Psychiatry 157(12), 1973-1979 (2000).
   Google Scholar
• Sussman N. The uses of buspirone in psychiatry. J. Clin. Psych. Monograph 12 (1), 3–19 (1994).
   Google Scholar
• Feighner J. Overview of antidepressants currently used to treat anxiety disorders. J. Clin. Psych. 60\(Suppl. 22), 18–22 (1999).
   Google Scholar
• Blackwell B. Adverse effects of antidepressant drugs. Part 1: monoamine oxidase inhibitors and tricyclics. Drugs 21(3), 201–219 (1981).
   Google Scholar
• Andrews J, Nemeroff C. Contemporary management of depression. Am. J. Merl 97(6A), S24—S32 (1994).
   Google Scholar
• Pollack M, Zaninelli R, Goddard A et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. j Clin. Psych. 62(5), 350–357 (2001).
   Google Scholar
• Rickets K, Zaninelli R, McCafferty J, Bellew K, Iyengar M, Sheehan D. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am. BychMtry160(4), 749–756 (2003).
   PubMed Web of Science ®Google Scholar
• Stocchi F, Nordera G, Jokinen R et al Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J. Clin. Psych. 64(3), 250–258 (2003).
   Google Scholar
• ••A long-term double-blind continuation trial of paroxetine, demonstrating clear efficacy of this drug on a key anxiety scale (Hamilton Rating Scale for Anxiety) and its domains and well as in everyday functioning. The work shows clear benefits with paroxetine in generalized anxiety disorder (GAD) therapy both in terms of response, remission and maintenance of significant treatment gains at eight months of therapy.
   Google Scholar
• Connor K, Davidson J. Generalized anxiety disorder: neurobiological and pharmacotherapeutic perspectives. Biol. Psych. 44(12), 1286–1294 (1998).
   PubMed Web of Science ®Google Scholar
• Ressler K, Nemeroff C. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress. Anxiety12\(Suppl. 1), 2–19 (2000).
   Google Scholar
• Cunningham L. Efficacy and tolerability of once daily venlafaxine extended release (XR) in outpatients with major depression and melancholia. j Clin. Psych. 56, 450–458 (1997).
   Google Scholar
• Holliday S, Benneld P Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs 49(2), 280–294 (1995).
   PubMed Web of Science ®Google Scholar
• Thase M. Efficacy and tolerability of once- daily venlafaxine extended release (XR) in outpatients with major depression. The venlafaxine XR 209 study group. j Clin. Psych. 58(9), 393–398 (1997).
   Google Scholar
• Hackett D, Parks V, Salinas E. Evaluation of 3 dose levels of venlafaxine extended-release in nondepressed outpatients with generalized anxiety disorder. Presented at the 151st American Psychiatric Association Annual Meeting; May 1998. Toronto, Canada, (1998).
   Google Scholar
• Aguiar L, Haskins T, Rudolph R. Double- blind, placebo-controlled study of once-daily venlafaxine XR in outpatients with generalized anxiety disorder (GAD). Presented at the 151st American Psychiatric Association Annual Meeting May 1998. Toronto, Canada, (1998).
   Google Scholar
• Gelenberg A, Lydiard R, Rudolph R, Aguiar L, Haskins J, Salinas E. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAIVIA 283(23), 3082–3088 (2000). Demonstrates significant reductions in GAD symptomatology both with acute and long-term therapy (6 months) with venlafaxine extended -elease (XR). The results of this work point to higher response rates, higher remission and greater stability of response with venlafaxine XR treatment of GAD patients, and indicating that full benefits of therapy with venlafaxine XR are only attained with long-term therapy.
   Google Scholar
• Davidson J, DuPont R, Hedges D, Haskins J. Efficacy, safety and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. j Clin. Psych. 60(8), 528–535 (1999).
   Google Scholar
• Rickets K, Pollack M, Sheehan D, Haskins J. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am. j Psychiatry 157 (6), 968–974 (2000) .
   PubMed Web of Science ®Google Scholar
• Silverstone P, Salinas E. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. j Clin. Psych. 62(7), 523–529 (2001).
   Google Scholar
• Sheehan DV Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder. j Clin. Psych. 60\(Supp1. 22), 23–28 (1999).
   Google Scholar
• Katz I, Reynolds C, Alexopoulos G, Hackett D. Venlafaxine XR as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials. j Am. Ceriatr Soc. 50(1), 18–25 (2002).
   PubMed Web of Science ®Google Scholar
• Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: 24-week placebo-controlled dose-ranging study. Br. fiych. 179,15-22 (2001).
   Google Scholar
• Montgomery S, Sheehan D, Meoni P, Haudiquet V, Hackett D. Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. Psychiatr. Res. 36(4), 209–217 (2002).
   Google Scholar
• Ninan P. Dissolving the burden of generalized anxiety disorder. j Clin. Psych. 62 (Suppl. 19), 5–10 (2001).
   Google Scholar
• Perugi G, Frare F, Toni C, Ruffolo G, Torti C. Open-label evaluation of venlafaxine sustained release in outpatients with generalized anxiety disorder with comorbid major depression or dysthymia: effectiveness, tolerability and predictors of response. Neumpsychobiology 46 (3), 145–149 (2002).
   PubMed Web of Science ®Google Scholar
• Effexor XR (venlafaxine hydrochloride) Product Monograph, Wyeth Laboratories, NJ, USA (2003).
   Google Scholar
• Mayr B, Bonelli R. Severe headache with venlafaxine withdrawal. Ann. Pharmacother 37(7-8), 1145–1146 (2003).
   PubMed Web of Science ®Google Scholar
• Trenque TDP, Frances C, Millart H, Germain M. Reports of withdrawal syndrome with the use of SSRIs: a case/ noncase study in the french pharmacovigilance database. Pharmacoepiclemiol Drug Sal 11(4), 281–283 (2002).
   PubMed Web of Science ®Google Scholar
• Reeves R, Mack J, Beddingfield J. Shock- like sensations during venlafaxine withdrawal. Pharmacotherapy 23 (5), 678–681 (2003).
   PubMed Web of Science ®Google Scholar
• Haddad P. Antidepressant discontinuation syndromes. Drug- Sal 24 (3), 183–197 (2001).
   PubMed Web of Science ®Google Scholar
• Hedges D, Reimherr F, Strong R, Halls C, Rust C. An open trial of nefazodone in adult patients with generalized anxiety disorder. Psychopharmacol Bull. 32 (4), 671–676 (1996).
   PubMedGoogle Scholar
• Rickels K, Downing R, Schweizer E et al Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone and diazepam. Arch. Gen. Ptychiatry50,884 —895 (1993).
   Web of Science ®Google Scholar
• Zajecka J. The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings. Clin. Psych. 57\(Suppl. 2), 10–14 (1996).
   Google Scholar
• Spigset 0, Hagg S, Bate A. Hepatic injury and pancreatitis during treatment with serotonin reuptake inhibitors: data from the World Health Organization (WHO) database of adverse drug reactions. Int. Glitz Psychophatmacol 18(3), 157–161 (2003).
   Google Scholar
• Barlow D, Rapee R, Brown T Behavioral treatment of generalized anxiety disorder. Behavior Ther 23,551–570 (1992).
   Web of Science ®Google Scholar
• Ost L, Breitholtz E. Applied relaxation vs. cognitive therapy in the treatment of generalized anxiety disorder. fkhav. Res. Ther 38(8), 777–790 (2000).
   Google Scholar
• Borkovec T, Costello E. Efficacy of applied relaxation and cognitive—behavioral therapy in the treatment of generalized anxiety disorder. j Consult. Clin. Psycho" 61 (4), 611–619 (1993). An excellent dissection of the components of cognitive behavioural therapy that are specifically targeted at achieving effective gains in a variety of domains of GAD disability and impaired functioning. The work is a good approach to understanding the particular processes that facilitate improvements of psychotherapeutic interventions, lending support to the potential effectiveness of cognitive behavioural therapy in GAD as well as a number of alternative nonpharrnacologic approaches.
   Google Scholar
• White J, Keenan M, Brooks N. Stress control: a controlled comparative investigation of large group therapy for generalized anxiety disorder. fkhav. Ptychothec 20,97–114 (1992).
   Google Scholar
• Durham R, Murphy T, Allan T, Richard K, Treliving L, Fenton G. Cognitive therapy, analytic psychotherapy and anxiety management training for generalised anxiety disorder. BE j Psych. 165 (3), 315–323 (1994).
   Google Scholar
• Butler G, Fennell M, Robson P, Gelder M. Comparison of behavior therapy and cognitive behavior therapy in the treatment of generalized anxiety disorder. J Consult. Clin. Ptychol 59(1), 167–175 (1991).
   Google Scholar
• Dugas M, Ladouceur R, Leger E et al Group cognitive—behavioral therapy for generalized anxiety disorder: treatment outcome and long-term follow-up. J. Consult. Clin. Ptychol 71(4), 821–825 (2003). Demonstrates the effectiveness of cognitive behavioural therapy in both the resolution of GAD symptomatology and the maintenance of symptom gains at two years follow up. In addition, the authors have been able to show that cognitive behavioural therapy can be achieved akin individual such therapy in a cost-effective small group setting. This study is a very good indicator of the potential efficacy of cognitive behavioural treatments methods in remission and relapse prevention carried out in a cost-effective manner.
   Google Scholar
• Borkovec T, Newman M, Pincus A, Lytle R. A component analysis of cognitive—behavioral therapy for generalized anxiety disorder and the role of interpersonal problems. J Consult. Cita Psychol. 70(2), 288–298 (2002).
   Google Scholar
• Amtz A. Cognitive therapy versus applied relaxation as treatment of generalized anxiety disorder. Behav. Res. Thec 41 (6), 633–646 (2003).
   Google Scholar
• Wetherell J, Gatz M, Craske M. Treatment of generalized anxiety disorder in older adults. J Consult. Clin. Psychol. 71(1), 31–40 (2003).
   Google Scholar
• Stanley M, Hopko D, Diefenbach G, Bourland S, Rodriguez H, Wagener Cognitive—behavior therapy for late-life generalized anxiety disorder in primary care: preliminary findings. Am J Ceriatc Psychiatry 11(1), 92–96 (2003).
   PubMed Web of Science ®Google Scholar
• Stanley M, Beck J, Novy D et al Cognitive—behavioral treatment of late-life generalized anxiety disorder. J Consult. Clin. Psychol. 71(2), 309–319 (2003).
   Google Scholar
• Mohlman J, Gorenstein E, Kleber M, de JM, Gorman J, Papp L. Standard and enhanced cognitive—behavior therapy for late-life generalized anxiety disorder: two pilot investigations. Am. J Ceriatc Psych. 11(1), 24–32 (2003).
   PubMed Web of Science ®Google Scholar
• Durham R, Chambers J, MacDonald R, Power K, Major K Does cognitive—behavioural therapy influence the long-term outcome of generalized anxiety disorder? An 8–14 year follow-up of two clinical trials. Bychol Med 33(3), 499–509 (2003).
   Google Scholar
• Kupfer D, Frank E. The interaction of drug and psychotherapy in the long-term treatment of depression. J Affect. Disond 62(1-2), 131–137 (2001).
   PubMed Web of Science ®Google Scholar
• Power K, Simpson R, Swanson V, Wallace L. A controlled study of cognitive—behaviour therapy, diazepam and placebo, alone and in combination for the treatment of generalised anxiety. J. Anxiety Dis. 4,267–292 (1990).
   Web of Science ®Google Scholar
• Bond A, Wingrove J, Valerie CH, Lader M. Treatment of generalised anxiety disorder with a short course of psychological therapy, combined with buspirone or placebo. J. Affect Dis. 72 (3), 267–271 (2002).
   PubMed Web of Science ®Google Scholar
• Lydiard R, Ballenger J, Rickels K. A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam and placebo in outpatients with generalized anxiety disorder. Abecamil work group. J. Clin. Psych. 58\(Suppl. 11), 11–18 (1997).
   Google Scholar
• Frattola L, Garreau M, Piolti R et al Comparison of the efficacy, safety and withdrawal of alpidem and alprazolam in anxious patients. BE J Psych. 165 (2), 94–100 (1994).
   Google Scholar
• Ferreri M, Hantouche E. Recent clinical trials of hydroxyzine in generalized anxiety disorder. Acta Ptychiatc Stand. (Suppl. 393), 102–108 (1998).
   PubMed Web of Science ®Google Scholar
• Lader M, Scotto J. A multicentre double- blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology139(4), 402–406 (1998).
   PubMed Web of Science ®Google Scholar
• Llorca P, Spadone C, Sol 0 et al Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study. J Clin. Psych. 63 (11), 1020–1027 (2002).
   Google Scholar
• Freeman A, Westphal J, Norris G et al Efficacy of ondansetron in the treatment of generalized anxiety disorder. Depress. Anxiety5(3), 140–141 (1997).
   PubMedGoogle Scholar
• Moller H, Volz H, Reimann I, Stoll K. Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J. Clin. Psychopharmacol 21(1), 59–65 (2001).
   Google Scholar
• Pande A, Crockatt J, Feltner D et al Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am. J Psych. 160(3), 533–540 (2003).
   PubMed Web of Science ®Google Scholar